Author + information
- Received July 20, 2012
- Revision received March 19, 2013
- Accepted March 20, 2013
- Published online October 1, 2013.
- Toru Kubo, MD∗,
- Hiroaki Kitaoka, MD∗∗ (, )
- Shigeo Yamanaka, MB†,
- Takayoshi Hirota, MD∗,
- Yuichi Baba, MD∗,
- Kayo Hayashi, MD∗,
- Tatsuo Iiyama, MD‡,
- Naoko Kumagai, MS‡,
- Katsutoshi Tanioka, MD∗,
- Naohito Yamasaki, MD∗,
- Yoshihisa Matsumura, MD∗,
- Takashi Furuno, MD∗,
- Tetsuro Sugiura, MD† and
- Yoshinori L. Doi, MD∗
- ∗Department of Medicine and Geriatrics, Kochi Medical School, Kochi, Japan
- †Department of Laboratory Medicine, Kochi Medical School, Kochi, Japan
- ‡Clinical Trial Center, Kochi Medical School, Kochi, Japan
- ↵∗Reprints and correspondence:
Dr. Hiroaki Kitaoka, Department of Medicine and Geriatrics, Kochi Medical School, Oko-cho, Nankoku-shi, Kochi 783-8505, Japan.
Objectives This study investigated the significance of the serum high-sensitivity cardiac troponin T (hs-cTnT) marker for prediction of adverse events in hypertrophic cardiomyopathy (HCM).
Background Although serum cardiac troponins as sensitive and specific markers of myocardial injury have become well-established diagnostic and prognostic markers in acute coronary syndrome, the usefulness of hs-cTnT for prediction of cardiovascular events in patients with HCM is unclear.
Methods We performed clinical evaluation, including measurements of hs-cTnT in 183 consecutive patients with HCM.
Results Of 183 HCM patients, 99 (54%) showed abnormal hs-cTnT values (>0.014 ng/ml). During a mean follow-up of 4.1 ± 2.0 years, 32 (32%) of the 99 patients in the abnormal hs-cTnT group, but only 6 (7%) of 84 patients with normal hs-cTnT values, experienced cardiovascular events: cardiovascular deaths, unplanned heart failure admissions, sustained ventricular tachycardia, embolic events, and progression to New York Heart Association functional class III or IV status (hazard ratio [HR]: 5.05, p < 0.001). Abnormal hs-cTnT value remained an independent predictor of these cardiovascular events after multivariate analysis (HR: 3.23, p = 0.012). Furthermore, in the abnormal hs-cTnT group, overall risk increased with an increase in hs-cTnT value (HR: 1.89/hs-cTnT 1 SD increase in the logarithmic scale, 95% confidence interval: 1.13 to 3.15; p = 0.015 [SD: 0.59]).
Conclusions In patients with HCM, an abnormal serum concentration of hs-cTnT is an independent predictor of adverse outcome, and a higher degree of abnormality in hs-cTnT value is associated with a greater risk of cardiovascular events.
All authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received July 20, 2012.
- Revision received March 19, 2013.
- Accepted March 20, 2013.
- 2013 American College of Cardiology Foundation